The Glucokinase Activator to Target HbA1c (AGATA) clinical trial evaluated the efficacy of TTP399 over a 6-month period in 190 patients with T2DM who were receiving a stable dose of metformin [51]. This evidence concerns the gene GCK and type 2 diabetes mellitus.